Heidelberg Pharma AG (LTS:0QW5) ROE % Adjusted to Book Value : -17.88% (As of Aug. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Heidelberg Pharma AG ROE % Adjusted to Book Value?

Heidelberg Pharma AG's ROE % for the quarter that ended in Aug. 2024 was -58.12%. Heidelberg Pharma AG's PB Ratio for the quarter that ended in Aug. 2024 was 3.25. Heidelberg Pharma AG's ROE % Adjusted to Book Value for the quarter that ended in Aug. 2024 was -17.88%.

Heidelberg Pharma AG ROE % Adjusted to Book Value Historical Data

The historical data trend for Heidelberg Pharma AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG ROE % Adjusted to Book Value Chart

Heidelberg Pharma AG Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-8.98

-13.69

-7.82

-15.01

-13.29

Heidelberg Pharma AG Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															0.28	-13.55	-12.08	-11.51	-17.88

Competitive Comparison of Heidelberg Pharma AG's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Heidelberg Pharma AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heidelberg Pharma AG's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's ROE % Adjusted to Book Value falls into.

Heidelberg Pharma AG ROE % Adjusted to Book Value Calculation

Heidelberg Pharma AG's ROE % Adjusted to Book Value for the fiscal year that ended in Nov. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-35.08%	/	2.64
	=	-13.29%

Heidelberg Pharma AG's ROE % Adjusted to Book Value for the quarter that ended in Aug. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-58.12%	/	3.25
	=	-17.88%

Heidelberg Pharma AG ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (LTS:0QW5) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

HPHA:Germany

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Heidelberg Pharma AG Headlines

No Headlines